ADC Therapeutics (ADCT) Asset Writedowns and Impairment (2022 - 2026)

ADC Therapeutics has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $1.5 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment rose 18.22% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 24.55% YoY) and the FY2025 annual result came in at $2.3 million, up 50.46% from the prior year.
• Asset Writedowns and Impairment climbed to $1.5 million in Q1 2026 per ADCT's latest filing, from $411000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $1.9 million in Q2 2022 and troughed at -$539000.0 in Q4 2022.
• A 5-year average of $637000.0 and a median of $482000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment slumped 62.47% in 2023, then soared 1311.32% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at -$539000.0 in 2022, then jumped by 253.62% to $828000.0 in 2023, then slumped by 41.79% to $482000.0 in 2024, then retreated by 14.73% to $411000.0 in 2025, then soared by 258.39% to $1.5 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.5 million, $411000.0, and $237000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.